-
Study aim
-
Comparison of changes in intestinal microbiome, oxidative stress indices, pain intensity, fatigue severity and depression between two groups of MS patients receiving probiotic supplement and placebo and within each group before and after the intervention
-
Design
-
A double-blind, randomized controlled clinical trial with a control group with a sample size of 50 subjects
-
Settings and conduct
-
Patients receive supplements and placebo in weeks zero, four and eight . Patients will be advised to take 2 capsules daily after lunch. The duration of the intervention is 12 weeks and all patients are enrolled in the MS Association of Khuzestan Province in Ahvaz Golestan Hospital. Researcher and participants have been blinded to the end of the intervention.
-
Participants/Inclusion and exclusion criteria
-
Diagnosis based on Mc Donald and MRI criteria EDSS score is less than 3 exclude criteria: Consumption of any probiotic and prebiotic and antibiotic supplement or supplement in the last 1 month Taking non-steroidal anti-inflammatory drugs NSAIDs, estrogen, progesterone, immunosuppressions, diuretics and corticosteroids
-
Intervention groups
-
Group A (probiotic): daily intake of two capsules Group B (placebo): A placebo similar to that of high-quality sacchar from corn starch (prepared by the company Protexin). Each probiotic capsule containing probiotic contains 109 * 2 * CFU /g of each species of Lactobacillus acidophilus, Lactobacillus casei , Bifidobacterium bifidum and Lactobacillus fermentum, Lactobacillus bulgaricus and Streptococcus thermophilus.
-
Main outcome variables
-
Intensity of pain, fatigue, depression and intestinal microbiome